It is increasingly accepted that, in breast cancer, the dissemination of tumour cells from the primary site to specific niches in the bone marrow is an early event, completed prior to diagnosis and initiation of therapy. Tumour cells can remain dormant in the bone marrow for decades and may never proliferate to form overt bone metastases. The precise cellular and molecular mechanisms that regulate tumour cell dormancy in bone, and the signals that trigger tumour cell escape from dormancy, remain to be established. However, the tumour microenvironment is suggested to play a major role in both processes, and therefore represents a key therapeutic target (1-2).
Development and progression of breast cancer bone metastases has been intensely studied, demonstrating that the process is driven by close interactions between tumour cells and components of the bone microenvironment. In particular, tumour cell-mediated stimulation of the bone-resorbing osteoclasts is shown to be responsible for the lytic bone lesions associated with late stage disease (3) . In contrast, our understanding of the early stages of tumour cell dissemination to the skeleton, as well as the initiation of tumour cell growth, is less clearly defined. Both osteoblasts and osteoclasts, as well as components of the extracellular matrix, are proposed to play a role in the early stages of bone metastasis (reviewed in: 3,4).
Due to the key role of the bone microenvironment, treatment of overt bone metastases involves a combination of agents that target tumour cells directly as well as bone-targeted agents like bisphosphonates and denosumab (5, 6) . However, whether adjuvant targeting of the bone microenvironment (in particular the osteoclast) can reduce bone metastasis remains controversial. The recently published AZURE trial found that treating breast cancer patients considered at high risk of developing bone metastases with
Zoledronic acid was only beneficial in patients with established menopause (7) . This surprising result has been confirmed in other clinical trials, but the underlying mechanisms are yet to be identified. Adjuvant trials of denosumab are ongoing (D-CARE), and will provide further information as to whether osteoclast-mediated processes are key to the differential effects on breast cancer bone metastasis according to menopausal status. (13) . However, denosumab is human specific and cannot be used in murine in vivo models. Instead we have used OPG-Fc, a potent inhibitor osteoclastogenesis that acts by preventing RANKL-RANK binding and hence modifies the same pathways as denosumab (14) . We investigated the effects of inhibiting OVX-induced bone resorption through targeting RANKL-RANK interactions in an in vivo model of disseminated breast cancer cells in bone.
The current study is the first to demonstrate that administration of OPG-Fc inhibits OVX-induced growth of disseminated, dormant, tumour cells in bone in vivo. Our data support the early administration of anti-resorptive therapy in a low-oestrogen setting to prevent development of bone metastases.
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Results
Effects of ovariectomy on growth of dormant breast cancer cells in bone
We have previously shown that ovariectomy (OVX) increases bone turnover in 12-week old mice and that performing OVX, either 7 days before or 7 days after intra-cardiac (i.c.)
injection of breast cancer cells, results in significantly increased bone metastasis (8) . These data demonstrate that tumour cells can remain dormant in bone for prolonged periods of time in vivo, and that altering the bone microenvironment through OVX triggers their proliferation and development into overt bone metastases. We next investigated whether the OVX-induced changes to the bone microenvironment could be counteracted by inhibition of bone turnover. Osteoprotegerin (OPG) inhibits osteoclastogenesis through disrupting RANKL-RANK interactions (14) . We established the effects of weekly administration of 25mg/kg OPG-Fc on the bone microenvironment in our model system. As shown in figure 2, animals receiving OPG-Fc displayed increased bone volume, had an extended growth plate and reduced serum levels of markers of both osteoclast (TRAP) and osteoblast (P1NP) activity, compared to the control group. This was accompanied by striking reductions in the numbers of osteoblasts and osteoclasts (figure 2a). Luciferase imaging showed no effect of OPG-Fc on tumour grown outside of bone (figure 4d) This is the first demonstration that administration of OPG-Fc has profound inhibitory effects on disseminated tumour cells in vivo, preventing development of overt bone metastases.
Effects of OPG-Fc on the bone microenvironment
OPG-Fc prevents OVX-induced changes to the bone microenvironment
In order to confirm that administration of OPG-Fc reversed OVX-induced bone loss, we carried out a detailed characterisation of the tibia of the animals in the tumour study described in the previous section. As shown in figure 5 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 Safranin O staining revealed that the enlarged growth plates were made up of proteoglycan with increased numbers of chondrocytes, indicating that inhibition of osteoclast activity is modifying endochondral ossification in this model. However, as the primary goal of this study was to investigate the effects on inhibiting RANK-RANKL interactions on tumour growth in bone, the effects of OPG-Fc on chondrocytes will be the subject of separate investigations.
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